苄氧基试卤灵 | 87687-02-3

• 物质功能分类: 生物化工 - 生化试剂 - 荧光成像
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 苄氧基试卤灵
• 中文别名: 7-苄氧基-3H-吩恶嗪-3-酮；7-苄氧基试卤灵
• 英文名称: 7-benzyloxyresorufin
• 英文别名: Benzyloxyresorufin；7-benzoxyresorufin；7-phenylmethoxyphenoxazin-3-one
• CAS: 87687-02-3
• 化学式: C₁₉H₁₃NO₃
• 分子量: 303.317
• InChiKey: XNZRYTITWLGTJS-UHFFFAOYSA-N

物化性质

• 熔点：
  148 - 151°C
• 沸点：
  479.9±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微）、DMSO（非常轻微）、甲醇（非常轻微）
• 稳定性/保质期：

  按规定使用和贮存的不会分解，避免接触氧化物和光照。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  47.9
• 氢给体数：
  0
• 氢受体数：
  4

ADMET

代谢

7-苄氧基洛若素分已知的人类代谢物包括洛若素。

7-Benzyloxyresorufin has known human metabolites that include Resorufin.

来源:NORMAN Suspect List Exchange

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Resorufin benzyl ether
CAS-No. : 87687-02-3

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
Causes skin irritation.
Causes serious eye irritation.
May cause respiratory irritation.
Precautionary statement(s)
Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Safety data sheet available on request.
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 7-Benzyloxy-3H-phenoxazin-3-one
7-Benzyloxyresorufin
O7-Benzylresorufin
Formula : C19H13NO3
Molecular Weight : 303,31 g/mol
Component Concentration
7-Benzyloxyresorufin
CAS-No. 87687-02-3 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Light sensitive.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
Colour: dark brown, red
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  苄氧基试卤灵 在 feline cytochrome P₄₅₀ 1A₂ isoform 作用下， 以 aq. phosphate buffer 为溶剂， 生成 试卤灵
  参考文献：
  名称：

  使用荧光底物对四种猫科动物P450细胞色素的功能性表达和比较表征。

  摘要：

  1.细胞色素P450（CYP）是人类和其他哺乳动物中异生素的主要代谢酶。CYP同工型在家猫（一种专食的食肉动物）中的特性目前尚不清楚。在这项研究中，我们研究了9种重要的猫CYP亚型在组织中的相对表达和酶学性质。 2. CYP2E2转录本在猫肝中含量最高，其次是CYP2A13和2E1。肝脏中也存在CYP3A131、1A2和1A1的转录本，而CYP2D6和3A132仅略有表达。CYP3A131是小肠的主要转录本。 3.猫肝和小肠中的四种主要CYP亚型（CYP1A2，CYP2A13，CYP2E2和CYP3A131）在大肠杆菌中异源表达，以生成功能性单加氧酶系统。我们进行了对17种已知在其他哺乳动物中是CYP亚型抑制剂的测试化合物的筛选，以及两种抗癌药物，以评估使用荧光底物的猫CYP亚型的活性调节。这些CYP亚型对其他抑制剂的选择性总体上与其他哺乳动物中的CYP同工型相似，但有许多例外。 4.本研

  DOI：

  10.1080/00498254.2016.1257172
• 作为产物：
  描述：

  溴甲苯 、 7-hydroxy-3H-phenoxazin-3-one sodium salt 在 potassium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 4.0h， 以54%的产率得到苄氧基试卤灵
  参考文献：
  名称：

  基于resorufin的荧光还原探针对硝基还原酶活性的响应及其在细菌检测中的应用

  摘要：

  我们目前响应于硝基还原酶（NTR）活性（NTR探针1和2）的两个基于Resorufin的荧光开启探针，以及它们对细菌检测的用途。探针响应NTR活性在586 nm处显示荧光开启，这对应于鲜艳的粉红色。这些光学变化是基于NTR介导的探针中硝基的还原，从而导致产生高荧光的试卤灵。已对NTR活性探针的检测能力，机理和酶动力学进行了彻底的研究。探针的酶效率优于先前报道的那些。此外，NTR探头1与2相比，具有很高的选择性和无背景信号的NTR表现出优异的检测能力。而且，NTR探针1适用于使用免洗过程的细菌检测，因为它响应于细菌的NTR活性而产生了荧光开启信号。

  DOI：

  10.1016/j.dyepig.2019.107779

文献信息

• Inhibition of Human Drug Metabolizing Cytochrome P450 by Buprenorphine.
  作者：Ken Umehara、Yoshihiko Shimokawa、Gohachiro Miyamoto

  DOI：10.1248/bpb.25.682

  日期：——

  The effects of buprenorphine, a powerful mixed agonist/antagonist analgesic, on several cytochrome P450 (CYP) isoform specific reactions in human liver microsomes were investigated to predict drug interaction of buprenorphine in vivo from in vitro data. The following eight CYP-catalytic reactions were used in this study: CYP1A1/2-mediated 7-ethoxyresorufin O-deethylation, CYP2A6-mediated coumarin 7-hydroxylation, CYP2B6-mediated 7-benzyloxyresorufin O-debenzylation, CYP2C8/9-mediated tolbutamide methylhydroxylation, CYP2C19-mediated S-mephenytoin 4-hydroxylation, CYP2D6-mediated bufuralol 1′-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, and CYP3A4-mediated testosterone 6β-hydroxylation. Buprenorphine strongly inhibited the CYP3A4- and CYP2D6-catalyzed reactions with Ki values of 14.7 μM and 21.4 μM, respectively. The analgesic also weakly inhibited specific reactions catalyzed by CYP1A1/2 (Ki=132 μM), CYP2B6 (Ki=133 μM), CYP2C19 (Ki=146 μM), CYP2C8/9 (IC50>300 μM), and CYP2E1 (IC50>300 μM), but not CYP2A6 mediated pathway. In consideration of the Ki values obtained in this study and the therapeutic concentration of buprenorphine in human plasma, buprenorphine would not be predicted to cause clinically significant interactions with other CYP-metabolized drugs.

  本研究调查了强效混合激动剂/拮抗剂镇痛药丁丙诺啡在人肝微粒体中对几种细胞色素P450（CYP）同工酶特异性反应的影响，旨在从体外数据预测丁丙诺啡在体内的药物相互作用。本研究使用了以下八种CYP催化反应：CYP1A1/2介导的7-乙氧基罗丹明O-脱乙基化、CYP2A6介导的香豆素7-羟化、CYP2B6介导的7-苄氧基罗丹明O-脱苄基化、CYP2C8/9介导的甲苯磺丁脲甲基羟化、CYP2C19介导的S-美芬妥英4-羟化、CYP2D6介导的布非洛尔1′-羟化、CYP2E1介导的氯唑沙宗6-羟化和CYP3A4介导的睾酮6β-羟化。丁丙诺啡对CYP3A4和CYP2D6催化反应显示出强烈抑制作用，Ki值分别为14.7 μM和21.4 μM。该镇痛药还对CYP1A1/2（Ki=132 μM）、CYP2B6（Ki=133 μM）、CYP2C19（Ki=146 μM）、CYP2C8/9（IC50>300 μM）和CYP2E1（IC50>300 μM）介导的特异性反应表现出弱抑制作用，但不包括CYP2A6介导的通路。综合本研究获得的Ki值和丁丙诺啡在人血浆中的治疗浓度，预计丁丙诺啡不会引起与其他CYP代谢药物临床意义上的显著相互作用。
• [EN] COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS<br/>[FR] COMPOSÉS, PROCÉDÉ D'OBTENTION DES COMPOSÉS, COMPOSITION PHARMACEUTIQUE, UTILISATION DES COMPOSÉS ET PROCÉDÉ DE TRAITEMENT DE TROUBLES PSYCHIATRIQUES ET/OU DE TROUBLES DU SOMMEIL
  申请人：ACHE LABORATORIOS FARMACEUTICOS SA

  公开号：WO2018076090A1

  公开（公告）日：2018-05-03

  The present invention relates to novel and inventive pharmacologically active benzimidazole derivative compounds, which surprisingly have high affinity for melatonin MTi and MT2 receptors and low affinity for CYP450 complex enzymes f specially CYP1A2. The present, invention also relates to novel and inventive routes of synthesis of these compounds, pharmaceutical compositions comprising the compounds and the use of these compounds in the treatment of individuais affected by psychiatric disorders and/or sleep disorders related to these receptors (specially depression, anxiety, circadian cycle disorders), in addition to process for producing the composition.

  本发明涉及一种新颖和创新的药理活性苯并咪唑衍生物化合物，这些化合物出人意料地具有高亲和力的褪黑激素MT1和MT2受体，并对CYP450复合酶f，特别是CYP1A2具有低亲和力。本发明还涉及这些化合物的新颖和创新的合成途径，包括这些化合物的药物组合物和将这些化合物用于治疗受精神障碍和/或与这些受体相关的睡眠障碍的个体（特别是抑郁症、焦虑症、昼夜节律紊乱），以及生产该组合物的方法。
• Beta-carbolin-derivates as substrates for an enzyme
  申请人：Julius-Maximilians-Universität Würzburg

  公开号：EP2151441A1

  公开（公告）日：2010-02-10

  The invention concerns a first compound of formula or

  这个发明涉及到一个化学式为的第一化合物。
• PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Zipfel Gregory

  公开号：US20120035359A1

  公开（公告）日：2012-02-09

  The present invention encompasses phenoxazine derivatives and methods of use thereof.

  本发明涵盖苯氧噻嗪衍生物及其使用方法。
• DERIVATIVES OF DILLAPIOL AND RELATED MONOLIGNANS AND USE THEREOF
  申请人：Arnason John Thor

  公开号：US20130012477A1

  公开（公告）日：2013-01-10

  Derivatives of dillapiol, sesamol and related monolignans having the following general formula: These compounds have synergistic properties, inhibit cytochrome P450 enzymes such as human CYP3A4, and can be used as pesticide synergists or pharmaco-enhancers. Accordingly, methods for increasing the efficacy and/or bioavailability of a pharmaceutically active agent and for increasing the potency of a pesticide are described, as are synergistic pesticidal and pharmaceutical compositions.

  dillapiol、sesamol及相关单木脂素的衍生物具有以下通用式：这些化合物具有协同作用，抑制细胞色素P450酶，如人类CYP3A4，并可用作杀虫剂增效剂或药物增强剂。因此，本文描述了增加药物活性剂的功效和/或生物利用度以及增加杀虫剂效力的方法，以及协同杀虫剂和药物组合物。